Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer’s disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery

What is it about?

In 2011, we developed blood brain barrier (BBB) crossing nanoparticles (NPs) (Grabrucker et al., 2011, PLoSOne) that deliver. In 2015 (Chhabra et al., CNS Neurol Disord Drug Targets), we applied this nanotechnology for the first time in vivo and could show that zinc can be fast and selectively enriched in the brain. This publication reports the result after application of these nanoparticles in a mouse model for Alzheimer's Disease (AD). We could show that our nanocarriers are able to reduce the plaque load in the brain of AD mice.

Featured Image